Belvarafenib (TFA)

• Description :

  Belvarafenib TFA (HM95573 TFA) is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC50s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively[1].

• Product Name Alternative :

  HM95573 (TFA) ; GDC-5573 (TFA) ; RG6185 (TFA)

• UNSPSC :

  12352005

• Target :

  Raf

• Type :

  Reference compound

• Related Pathways :

  MAPK/ERK Pathway

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/belvarafenib-tfa.html

• Purity :

  99.0

• Solubility :

  10 mM in H2O

• Smiles :

  O=C(C(C1=NC=N2)=CSC1=C2N)NC(C3=C4C(NC(C=CC=C5Cl)=C5F)=NC=C3)=C(C=C4)C.OC(C(F)(F)F)=O

• Molecular Formula :

  C25H17ClF4N6O3S

• Molecular Weight :

  592.95

• References & Citations :

  [1]WO 2013/100632 A1.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• CAS Number :

  [2443966-84-3]